LL-37
Human Cathelicidin — Antimicrobial & Immune Peptide
LL-37 is the only human cathelicidin — the sole member of this antimicrobial peptide family expressed in humans. Produced by neutrophils, keratinocytes, and epithelial cells, it serves a dual role as both a direct antimicrobial agent (killing bacteria, fungi, and enveloped viruses) and an immune signaling peptide that modulates inflammatory responses and wound healing.
At a Glance
Cathelicidins are part of the innate immune system — the first-line defense that acts before adaptive immunity. LL-37 disrupts microbial membranes via cationic amphipathic structure, kills a broad spectrum of organisms including antibiotic-resistant strains, and simultaneously signals to immune cells to coordinate the inflammatory and repair response.
This dual antimicrobial + immunomodulatory profile is LL-37's defining research characteristic — it bridges the gap between killing pathogens and organizing the healing response that follows.
Biofilm disruption is an increasingly important research application — LL-37 can penetrate and disrupt established bacterial biofilms that antibiotic drugs cannot reach, making it relevant to the growing antimicrobial resistance research space.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
Direct Antimicrobial Activity
Inserts into and disrupts bacterial, fungal, and viral membranes via cationic amphipathic mechanism — effective against antibiotic-resistant strains and biofilms.
Innate Immune Coordination
Binds TLR4, formyl peptide receptors, and purinergic receptors on immune cells — coordinating neutrophil recruitment, macrophage activation, and inflammatory resolution.
Wound Healing Acceleration
Promotes keratinocyte migration, angiogenesis, and matrix remodeling — bridging antimicrobial and repair functions in skin wound models.
Biofilm Disruption
Penetrates bacterial biofilm matrices and disrupts the structural integrity — effective where conventional antibiotics fail to penetrate.
Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.
- Wound healing — chronic wound and surgical wound models; keratinocyte and angiogenesis promotion
- Antimicrobial resistance — activity against MRSA, P. aeruginosa, and other resistant pathogens
- Biofilm disruption — penetration and disruption of established biofilms
- Skin defense — atopic dermatitis (reduced LL-37 associated with increased infection susceptibility)
- Respiratory infections — lung epithelial defense against bacterial and viral pathogens
- Anti-inflammatory — modulation of TLR4 and LPS-induced inflammation
- Sepsis research — LL-37's LPS neutralization and immunomodulation in endotoxemia models
LL-37's antimicrobial + repair dual function makes it uniquely valuable in research contexts where both pathogen clearance and tissue recovery are study variables.
LL-37, BPC-157, and Thymosin Alpha-1 cover the antimicrobial, structural repair, and adaptive immune dimensions of tissue healing research.
| Aspect | LL-37 | BPC-157 | Thymosin Alpha-1 |
|---|---|---|---|
| Antimicrobial | Direct — membrane disruption | None | None |
| Immune Modulation | Innate coordination | Secondary (indirect) | T-cell/DC activation (adaptive) |
| Wound Healing | Yes — keratinocyte + angiogenesis | Yes — primary mechanism | Indirect |
| Biofilm Activity | Yes | No | No |
| Best Research Use | Antimicrobial resistance, innate immunity | Tissue repair | Viral/adaptive immunity |
The following reflects findings from published preclinical and clinical safety assessments where available.
Only human cathelicidin — the sole member of this antimicrobial peptide family in humans; unique research position
Dual antimicrobial + repair mechanism — covers both pathogen clearance and healing promotion
Biofilm activity — relevant to antibiotic resistance research where conventional drugs fail
Potential toxicity at high doses — cationic membrane disruption mechanism is non-selective at high concentrations; therapeutic window is important in research design
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026